Loading...
It's been another fascinating year in gastroenterology research. Much of this year's literature either confirms that our current practice is “best evidence” or indicates that it is likely to change soon due to new evidence.
In the esophagus, we now have overwhelming evidence that proton-pump inhibitors (PPIs) do not lead to increased cardiovascular risk or undo the benefits of cardiovascular treatments. Thus, there is no compelling reason why PPI therapy cannot or should not be used in patients on cardiovascular therapies. Additionally, whether we should be screening and/or performing surveillance for Barrett esophagus has been debatable, especially now that the real risk for neoplasia has been demonstrated to be very low.
In the stomach, we …